Theranostics – Emerging Trends and Future Direction in Personalized Medicine

Program Sponsors:

This presentation provides an overview of theranostics as a precision medicine approach that pairs molecular imaging with targeted radioligand therapy to diagnose, treat, and monitor cancer using the same biologic target. It highlights the clinical evolution of theranostics from early radioactive iodine therapy to today’s expanding use of PSMA- and neuroendocrine-targeted radiopharmaceuticals, emphasizing the rapid growth of clinical indications and therapeutic volume.  The content also outlines major trends shaping the field, including earlier adoption in prostate cancer, a growing pipeline of new targets and isotopes, increasing clinical trial activity, and continued investment from large pharmaceutical companies.  From an operational perspective, the presentation underscores the importance of advanced PET/CT and SPECT/CT technology, AI-enabled workflow tools, quantitative imaging, and scalable infrastructure to support efficient, high-quality theranostics programs.  Overall, it positions theranostics as a rapidly growing care model that requires coordinated imaging, therapy, radiopharmacy, and clinical pathways to improve patient access, streamline delivery, and support better outcomes at scale.

Learning Objectives: 

• Understand how molecular imaging guides patient-specific diagnostics and treatment planning across various disease states
• Review recent innovations in PET/CT and SPECT/CT imaging technologists that improve diagnostic accuracy, workflow efficiency, and patient outcomes
• Discuss emerging trends, clinical applications, and the evolving role of theranostics in precision medicine, including potential impacts on patient care and healthcare delivery

Speaker: 

• • Jamie Raney, Care Pathway Leader, Theranostics Strategy & Growth, USCAN

    Jamie Raney is a seasoned healthcare executive with over two decades of experience in nuclear medicine, theranostics, and imaging operations. Currently serving as the Care Pathway Leader for Theranostics Strategy and Growth at GE HealthCare, Jamie partners with providers across the U.S. and Canada to enable and optimize cutting-edge theranostics programs that elevate patient care and operational efficiency.

    Jamie's career spans leadership roles in both clinical and corporate settings, including as Regional Director of Operations at CDL Nuclear Technologies, Director of Imaging and Nuclear Medicine for Rocky Mountain Cancer Centers, and as Practice Administrator at BAMF Health, where he launched the clinical operations of a state-of-the-art Theranostics Center. His expertise also includes consulting for a national radiopharmacy network and serving as a Medical Science Liaison for Telix Pharmaceuticals, where he provided support in the pre-launch of illuccix as well as the research pipeline.

    With a strong foundation in nuclear medicine technology and a Master of Business Administration in Healthcare Management, Jamie brings a unique blend of clinical insight and strategic acumen. He is a Certified Nuclear Medicine Technologist and an active member of the Society of Nuclear Medicine and Molecular Imaging.

    Jamie is passionate about advancing theranostics and molecular imaging to improve outcomes for patients and communities. His leadership is marked by a commitment to operational excellence, innovation, and collaborative growth.

This webinar is pending CE credit approval!